Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN63DZ)

• Drug Name: Moxetumomab pasudotox Drug Info
• Synonyms: CAT-8015; GCR-8015; HA22; UNII-2NDX4B6N8F; Moxetumomab pasudotox [USAN]; Immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 heavy chain variable region fragment) fusion protein with exotoxin PE38 (Pseudomonas fragment), disulfide with immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 light chain fragment)

Indication

Disease Entry	ICD 11	Status	REF
Hairy cell leukaemia	2A82.2	Approved	[1]
Haematological malignancy	2B33.Y	Phase 1	[2]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID: TTD Drug ID: DMN63DZ

Molecule-Related Drug Atlas

Drug(s) Targeting B-cell receptor CD22 (CD22)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Inotuzumab ozogamicin	DMAC130	Acute lymphoblastic leukaemia	2A85	Approved	[4]
OspA lipoprotein	DMF5ZB3	Lyme disease	1C1G	Approved	[5]
Epratuzumab	DMI1ZXV	Acute lymphoblastic leukaemia	2A85	Phase 3	[6]
CAR-T cells targeting CD22	DM6XN4C	Non-hodgkin lymphoma	2B33.5	Phase 2	[7]
BL-22	DM8R71T	Acute lymphoblastic leukaemia	2A85	Phase 2	[8]
CAR-T cells targeting CD22	DM6XN4C	Non-hodgkin lymphoma	2B33.5	Phase 2	[9]
AUTO3	DMC5NSO	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[10]
CART-19/22	DMX0R1E	leukaemia	2A60-2B33	Phase 1/2	[11]
CD19 and CD22 CAR-T Cells	DM581CS	B-cell lymphoma	2A86	Phase 1/2	[12]
4SCAR19/22 T cells	DMI8TW3	B-cell lymphoma	2A86	Phase 1/2	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell receptor CD22 (CD22)	TTM6QSK	CD22_HUMAN	Modulator	[3]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 761104.
• [2] Advances in the Development of Anti-CD22 Immunotoxins Containing Pseudomonas Exotoxin for Treatment of Hematologic Malignancies
• [3] Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405.
• [4] Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.
• [5] Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14.
• [6] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [7] ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
• [8] Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903.
• [9] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [10] ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
• [11] ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
• [12] ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
• [13] ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies